Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti-β2GPI antibodies. Our results confirmed that high avidity anti-β2GPI are associated with thrombosis and APS, while in low avidity anti-β2GPI group non-APS (predominantly systemic lupus erythematosus) patients prevailed. © The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav.
Avidity of anti-β2-glycoprotein i antibodies in patients with antiphospholipid syndrome / S., Cucnik; T., Kveder; A., Artenjak; Z., Ulcova Gallova; J., Swadzba; J., Musial; T., Iwaniec; L., Stojanovich; Alessandri, Cristiano; Valesini, Guido; T., Avcin; J. w., Cohen Tervaert; B., Rozman; B., Bozic. - In: LUPUS. - ISSN 0961-2033. - STAMPA. - 21:7(2012), pp. 764-765. [10.1177/0961203312440057]
Avidity of anti-β2-glycoprotein i antibodies in patients with antiphospholipid syndrome
ALESSANDRI, cristiano;VALESINI, Guido;
2012
Abstract
Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti-β2GPI antibodies. Our results confirmed that high avidity anti-β2GPI are associated with thrombosis and APS, while in low avidity anti-β2GPI group non-APS (predominantly systemic lupus erythematosus) patients prevailed. © The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
